fluorouracil has been researched along with 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergmann, F; Bläker, H; Breinig, M; Britsch, S; Ehemann, V; Fischer, L; Harjung, A; Kern, MA; Malz, M; Mayer, P; Scherübl, H; Schirmacher, P; Werner, J | 1 |
| Dibbern, JL; Ghadban, T; Güngör, C; Izbicki, JR; Miro, JT; Reeh, M; Tsui, TY; Vashist, YK; Wellner, U | 1 |
2 other study(ies) available for fluorouracil and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
| Article | Year |
|---|---|
Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Survival; Doxorubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Mice; Middle Aged; Multiple Endocrine Neoplasia Type 1; Pancreatic Neoplasms; RNA, Messenger; Young Adult | 2012 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence | 2017 |